KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

• Where is my product positioned vs. competitors in the treatment journey?

• What are physicians’ most frequent treatment sequences—who is benefiting, and how can I defend my asset’s share and position?

• What are the market-relevant treatment scenarios according to oncology experts?

• Where are the untapped business opportunities that I can capitalize upon?

• How can I optimize trial design and ensure a competitive edge for my pipeline asset?

GEOGRAPHIES

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. physicians

2019 COVERAGE

Colorectal Cancer (US)

Multiple Myeloma (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)

Non-Small-Cell Lung Cancer (US)

Ovarian Cancer (US)

Prostate Cancer (US)

Renal Cell Carcinoma (US)

KEY FEATURES

  • Market-relevant treatment scenarios and subpopulations from oncology experts.
  • Drug share and treatment rates mapped to the treatment journey based on physician survey data.
  • Physicians’ most frequently selected treatment sequences.
  • Access to expert oncology analysts for bespoke support.

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

Table of contents

  • Colorectal Cancer - Current Treatment - Detailed, Expanded Analysis (US): Treatment Sequencing
    • Treatment Sequencing Colorectal Cancer US August 2019

Author(s): Sudha Malhotra, Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.


Related Reports

Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the meta...

View Details

Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020

Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented...

View Details

Colorectal Cancer - Geographic Focus: China - Colorectal Cancer - China In-Depth (China)

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

View Details

Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

View Details